schliessen

Filtern

 

Bibliotheken

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Summary Background Expansion of access to effective treatments for heroin dependence is a worldwide health priority that will also reduce HIV transmission. We compared the efficacy of naltrexone, buprenorphine, and no additional treatment, in patients receiving detoxification and subsequent drug cou... Full description

Journal Title: The Lancet (British edition) 2008, Vol.371 (9631), p.2192-2200
Main Author: Schottenfeld, Richard S, MD
Other Authors: Chawarski, Marek C, PhD , Mazlan, Mahmud, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Link: https://www.ncbi.nlm.nih.gov/pubmed/18586174
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_crossref_primary_10_1016_S0140_6736_08_60954_X
title: Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
format: Article
creator:
  • Schottenfeld, Richard S, MD
  • Chawarski, Marek C, PhD
  • Mazlan, Mahmud, MD
subjects:
  • Adult
  • Buprenorphine - administration & dosage
  • Buprenorphine - adverse effects
  • Buprenorphine - therapeutic use
  • Counseling
  • Double-Blind Method
  • Heroin Dependence - complications
  • Heroin Dependence - drug therapy
  • HIV Infections - etiology
  • HIV Infections - prevention & control
  • Humans
  • Internal Medicine
  • Malaysia
  • Naltrexone - administration & dosage
  • Naltrexone - adverse effects
  • Naltrexone - therapeutic use
  • Narcotic Antagonists - administration & dosage
  • Narcotic Antagonists - adverse effects
  • Narcotic Antagonists - therapeutic use
  • Recurrence
  • Risk-Taking
  • Treatment Outcome
ispartof: The Lancet (British edition), 2008, Vol.371 (9631), p.2192-2200
description: Summary Background Expansion of access to effective treatments for heroin dependence is a worldwide health priority that will also reduce HIV transmission. We compared the efficacy of naltrexone, buprenorphine, and no additional treatment, in patients receiving detoxification and subsequent drug counselling, for maintenance of heroin abstinence, prevention of relapse, and reduction of HIV risk behaviours. Methods 126 detoxified heroin-dependent patients, from an outpatient research clinic and detoxification programme in Malaysia, were randomly assigned by a computer-generated randomisation sequence to 24 weeks of manual-guided drug counselling and maintenance with naltrexone (n=43), buprenorphine (n=44), or placebo (n=39). Medications were administered on a double-blind and double-dummy basis. Primary outcomes, assessed by urine testing three times per week, were days to first heroin use, days to heroin relapse (three consecutive opioid-positive urine tests), maximum consecutive days of heroin abstinence, and reductions in HIV risk behaviours over 6 months. The study was terminated after 22 months of enrolment because buprenorphine was shown to have greater efficacy in an interim safety analysis. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov , number NCT00383045. Findings We observed consistent, linear contrasts in days to first heroin use (p=0·0009), days to heroin relapse (p=0·009), and maximum consecutive days abstinent (p=0·0007), with all results best for buprenorphine and worst for placebo. Buprenorphine was associated with greater time to first heroin use than were naltrexone (hazard ratio 1·87 [95% CI 1·21–2·88]) or placebo (2·02 [1·29–3·16]). With buprenorphine, we also recorded significantly greater time to heroin relapse (2·17 [1·38–3·42]), and maximum consecutive days abstinent than with placebo (mean days 59 [95% CI 43–76] vs 24 [13–35]; p=0·003); however, for these outcomes, differences between buprenorphine and naltrexone were not significant. Differences between naltrexone and placebo were not significant for any outcomes. HIV risk behaviours were significantly reduced from baseline across all three treatments (p=0·003), but the reductions did not differ significantly between the three groups. Interpretation Our findings lend support to the widespread dissemination of maintenance treatment with buprenorphine as an effective public-health approach to reduce problems associated with heroin dependence. Fu
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.452675
LOCALfalse
PrimoNMBib
record
control
sourceidelsevier_cross
recordidTN_cdi_crossref_primary_10_1016_S0140_6736_08_60954_X
sourceformatXML
sourcesystemPC
sourcerecordidS014067360860954X
originalsourceidFETCH-LOGICAL-1582t-50ad75c7fb27839ca3a45c8aa9df8a2c706bab0eabc21ebc598cc155acbf21393
addsrcrecordideNqFkV1rFDEUhoModq3-BGUuFRxNZiYzGQWlFL-gxQsV9i6cJGfY1GwyJFnt_gr_spndotCbXoUXzvuE8xxCnjL6ilHWv_5GWUfrfmj751S86OnIu3p9j6xYN3Q174b1fbL6N3JCHqV0RSntesofkhMmuOjZ0K3In0uwPqMHr7HKESFv0efqt82bSu3miD7EeWM9VuBN5cGVmetQ4hRitcEYrK8MzugNLoSSLsHBPll4U0EVSylsbULzsjJhpxzWyllf0uxAowq1Dj7H4Bya8rsF95g8mMAlfHLznpIfHz98P_9cX3z99OX87KJmXDS55hTMwPUwqWYQ7aihhY5rATCaSUCjB9orUBRB6Yah0nwUWjPOQaupYe3YnhJ-5OoYUoo4yTnaLcS9ZFQuguVBsFzsSSrkQbBcl96zY2_eqS2a_60bo2Xg7S2wthmyXfYE6-7Evz-2sez-y2KUSdvFrLERdZYm2DsJ724RdDFuNbifuMd0FXaxXDFJJlMj6RGyMKg4ENbtXxGzt2c
sourcetypeAggregation Database
isCDItrue
recordtypearticle
display
typearticle
titleMaintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
sourceAlma/SFX Local Collection
creatorSchottenfeld, Richard S, MD ; Chawarski, Marek C, PhD ; Mazlan, Mahmud, MD
creatorcontribSchottenfeld, Richard S, MD ; Chawarski, Marek C, PhD ; Mazlan, Mahmud, MD
descriptionSummary Background Expansion of access to effective treatments for heroin dependence is a worldwide health priority that will also reduce HIV transmission. We compared the efficacy of naltrexone, buprenorphine, and no additional treatment, in patients receiving detoxification and subsequent drug counselling, for maintenance of heroin abstinence, prevention of relapse, and reduction of HIV risk behaviours. Methods 126 detoxified heroin-dependent patients, from an outpatient research clinic and detoxification programme in Malaysia, were randomly assigned by a computer-generated randomisation sequence to 24 weeks of manual-guided drug counselling and maintenance with naltrexone (n=43), buprenorphine (n=44), or placebo (n=39). Medications were administered on a double-blind and double-dummy basis. Primary outcomes, assessed by urine testing three times per week, were days to first heroin use, days to heroin relapse (three consecutive opioid-positive urine tests), maximum consecutive days of heroin abstinence, and reductions in HIV risk behaviours over 6 months. The study was terminated after 22 months of enrolment because buprenorphine was shown to have greater efficacy in an interim safety analysis. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov , number NCT00383045. Findings We observed consistent, linear contrasts in days to first heroin use (p=0·0009), days to heroin relapse (p=0·009), and maximum consecutive days abstinent (p=0·0007), with all results best for buprenorphine and worst for placebo. Buprenorphine was associated with greater time to first heroin use than were naltrexone (hazard ratio 1·87 [95% CI 1·21–2·88]) or placebo (2·02 [1·29–3·16]). With buprenorphine, we also recorded significantly greater time to heroin relapse (2·17 [1·38–3·42]), and maximum consecutive days abstinent than with placebo (mean days 59 [95% CI 43–76] vs 24 [13–35]; p=0·003); however, for these outcomes, differences between buprenorphine and naltrexone were not significant. Differences between naltrexone and placebo were not significant for any outcomes. HIV risk behaviours were significantly reduced from baseline across all three treatments (p=0·003), but the reductions did not differ significantly between the three groups. Interpretation Our findings lend support to the widespread dissemination of maintenance treatment with buprenorphine as an effective public-health approach to reduce problems associated with heroin dependence. Funding US National Institute on Drug Abuse.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(08)60954-X
3PMID: 18586174
languageeng
publisherEngland: Elsevier Ltd
subjectAdult ; Buprenorphine - administration & dosage ; Buprenorphine - adverse effects ; Buprenorphine - therapeutic use ; Counseling ; Double-Blind Method ; Heroin Dependence - complications ; Heroin Dependence - drug therapy ; HIV Infections - etiology ; HIV Infections - prevention & control ; Humans ; Internal Medicine ; Malaysia ; Naltrexone - administration & dosage ; Naltrexone - adverse effects ; Naltrexone - therapeutic use ; Narcotic Antagonists - administration & dosage ; Narcotic Antagonists - adverse effects ; Narcotic Antagonists - therapeutic use ; Recurrence ; Risk-Taking ; Treatment Outcome
ispartofThe Lancet (British edition), 2008, Vol.371 (9631), p.2192-2200
rights
0Elsevier Ltd
12008 Elsevier Ltd
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1582t-50ad75c7fb27839ca3a45c8aa9df8a2c706bab0eabc21ebc598cc155acbf21393
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18586174$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Schottenfeld, Richard S, MD
1Chawarski, Marek C, PhD
2Mazlan, Mahmud, MD
title
0Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
1The Lancet (British edition)
addtitleLancet
descriptionSummary Background Expansion of access to effective treatments for heroin dependence is a worldwide health priority that will also reduce HIV transmission. We compared the efficacy of naltrexone, buprenorphine, and no additional treatment, in patients receiving detoxification and subsequent drug counselling, for maintenance of heroin abstinence, prevention of relapse, and reduction of HIV risk behaviours. Methods 126 detoxified heroin-dependent patients, from an outpatient research clinic and detoxification programme in Malaysia, were randomly assigned by a computer-generated randomisation sequence to 24 weeks of manual-guided drug counselling and maintenance with naltrexone (n=43), buprenorphine (n=44), or placebo (n=39). Medications were administered on a double-blind and double-dummy basis. Primary outcomes, assessed by urine testing three times per week, were days to first heroin use, days to heroin relapse (three consecutive opioid-positive urine tests), maximum consecutive days of heroin abstinence, and reductions in HIV risk behaviours over 6 months. The study was terminated after 22 months of enrolment because buprenorphine was shown to have greater efficacy in an interim safety analysis. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov , number NCT00383045. Findings We observed consistent, linear contrasts in days to first heroin use (p=0·0009), days to heroin relapse (p=0·009), and maximum consecutive days abstinent (p=0·0007), with all results best for buprenorphine and worst for placebo. Buprenorphine was associated with greater time to first heroin use than were naltrexone (hazard ratio 1·87 [95% CI 1·21–2·88]) or placebo (2·02 [1·29–3·16]). With buprenorphine, we also recorded significantly greater time to heroin relapse (2·17 [1·38–3·42]), and maximum consecutive days abstinent than with placebo (mean days 59 [95% CI 43–76] vs 24 [13–35]; p=0·003); however, for these outcomes, differences between buprenorphine and naltrexone were not significant. Differences between naltrexone and placebo were not significant for any outcomes. HIV risk behaviours were significantly reduced from baseline across all three treatments (p=0·003), but the reductions did not differ significantly between the three groups. Interpretation Our findings lend support to the widespread dissemination of maintenance treatment with buprenorphine as an effective public-health approach to reduce problems associated with heroin dependence. Funding US National Institute on Drug Abuse.
subject
0Adult
1Buprenorphine - administration & dosage
2Buprenorphine - adverse effects
3Buprenorphine - therapeutic use
4Counseling
5Double-Blind Method
6Heroin Dependence - complications
7Heroin Dependence - drug therapy
8HIV Infections - etiology
9HIV Infections - prevention & control
10Humans
11Internal Medicine
12Malaysia
13Naltrexone - administration & dosage
14Naltrexone - adverse effects
15Naltrexone - therapeutic use
16Narcotic Antagonists - administration & dosage
17Narcotic Antagonists - adverse effects
18Narcotic Antagonists - therapeutic use
19Recurrence
20Risk-Taking
21Treatment Outcome
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2008
recordtypearticle
recordideNqFkV1rFDEUhoModq3-BGUuFRxNZiYzGQWlFL-gxQsV9i6cJGfY1GwyJFnt_gr_spndotCbXoUXzvuE8xxCnjL6ilHWv_5GWUfrfmj751S86OnIu3p9j6xYN3Q174b1fbL6N3JCHqV0RSntesofkhMmuOjZ0K3In0uwPqMHr7HKESFv0efqt82bSu3miD7EeWM9VuBN5cGVmetQ4hRitcEYrK8MzugNLoSSLsHBPll4U0EVSylsbULzsjJhpxzWyllf0uxAowq1Dj7H4Bya8rsF95g8mMAlfHLznpIfHz98P_9cX3z99OX87KJmXDS55hTMwPUwqWYQ7aihhY5rATCaSUCjB9orUBRB6Yah0nwUWjPOQaupYe3YnhJ-5OoYUoo4yTnaLcS9ZFQuguVBsFzsSSrkQbBcl96zY2_eqS2a_60bo2Xg7S2wthmyXfYE6-7Evz-2sez-y2KUSdvFrLERdZYm2DsJ724RdDFuNbifuMd0FXaxXDFJJlMj6RGyMKg4ENbtXxGzt2c
startdate2008
enddate2008
creator
0Schottenfeld, Richard S, MD
1Chawarski, Marek C, PhD
2Mazlan, Mahmud, MD
generalElsevier Ltd
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
sort
creationdate2008
titleMaintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
authorSchottenfeld, Richard S, MD ; Chawarski, Marek C, PhD ; Mazlan, Mahmud, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1582t-50ad75c7fb27839ca3a45c8aa9df8a2c706bab0eabc21ebc598cc155acbf21393
rsrctypearticles
prefilterarticles
languageeng
creationdate2008
topic
0Adult
1Buprenorphine - administration & dosage
2Buprenorphine - adverse effects
3Buprenorphine - therapeutic use
4Counseling
5Double-Blind Method
6Heroin Dependence - complications
7Heroin Dependence - drug therapy
8HIV Infections - etiology
9HIV Infections - prevention & control
10Humans
11Internal Medicine
12Malaysia
13Naltrexone - administration & dosage
14Naltrexone - adverse effects
15Naltrexone - therapeutic use
16Narcotic Antagonists - administration & dosage
17Narcotic Antagonists - adverse effects
18Narcotic Antagonists - therapeutic use
19Recurrence
20Risk-Taking
21Treatment Outcome
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Schottenfeld, Richard S, MD
1Chawarski, Marek C, PhD
2Mazlan, Mahmud, MD
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Schottenfeld, Richard S, MD
1Chawarski, Marek C, PhD
2Mazlan, Mahmud, MD
formatjournal
genrearticle
ristypeJOUR
atitleMaintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
jtitleThe Lancet (British edition)
addtitleLancet
date2008
risdate2008
volume371
issue9631
spage2192
epage2200
pages2192-2200
issn0140-6736
eissn1474-547X
abstractSummary Background Expansion of access to effective treatments for heroin dependence is a worldwide health priority that will also reduce HIV transmission. We compared the efficacy of naltrexone, buprenorphine, and no additional treatment, in patients receiving detoxification and subsequent drug counselling, for maintenance of heroin abstinence, prevention of relapse, and reduction of HIV risk behaviours. Methods 126 detoxified heroin-dependent patients, from an outpatient research clinic and detoxification programme in Malaysia, were randomly assigned by a computer-generated randomisation sequence to 24 weeks of manual-guided drug counselling and maintenance with naltrexone (n=43), buprenorphine (n=44), or placebo (n=39). Medications were administered on a double-blind and double-dummy basis. Primary outcomes, assessed by urine testing three times per week, were days to first heroin use, days to heroin relapse (three consecutive opioid-positive urine tests), maximum consecutive days of heroin abstinence, and reductions in HIV risk behaviours over 6 months. The study was terminated after 22 months of enrolment because buprenorphine was shown to have greater efficacy in an interim safety analysis. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov , number NCT00383045. Findings We observed consistent, linear contrasts in days to first heroin use (p=0·0009), days to heroin relapse (p=0·009), and maximum consecutive days abstinent (p=0·0007), with all results best for buprenorphine and worst for placebo. Buprenorphine was associated with greater time to first heroin use than were naltrexone (hazard ratio 1·87 [95% CI 1·21–2·88]) or placebo (2·02 [1·29–3·16]). With buprenorphine, we also recorded significantly greater time to heroin relapse (2·17 [1·38–3·42]), and maximum consecutive days abstinent than with placebo (mean days 59 [95% CI 43–76] vs 24 [13–35]; p=0·003); however, for these outcomes, differences between buprenorphine and naltrexone were not significant. Differences between naltrexone and placebo were not significant for any outcomes. HIV risk behaviours were significantly reduced from baseline across all three treatments (p=0·003), but the reductions did not differ significantly between the three groups. Interpretation Our findings lend support to the widespread dissemination of maintenance treatment with buprenorphine as an effective public-health approach to reduce problems associated with heroin dependence. Funding US National Institute on Drug Abuse.
copEngland
pubElsevier Ltd
pmid18586174
doi10.1016/S0140-6736(08)60954-X
oafree_for_read